Reducing Adverse Polypharmacy in Patients With Borderline Personality Disorder | Zendy

Alok Madan | Zendy; John M. Oldham | Zendy; S Espla Gonzalez | Zendy; J. Christopher Fowler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reducing Adverse Polypharmacy in Patients With Borderline Personality Disorder

Author(s) -

Alok Madan,

John M. Oldham,

S Espla Gonzalez,

J. Christopher Fowler

Publication year - 2015

Publication title -

the primary care companion for cns disorders

Language(s) - English

Resource type - Journals

eISSN - 2155-7772

pISSN - 2155-7780

DOI - 10.4088/pcc.14m01760

Subject(s) - polypharmacy , borderline personality disorder , context (archaeology) , psychiatry , medicine , impulsivity , anxiety , adverse effect , personality , clinical psychology , psychology , intensive care medicine , paleontology , social psychology , biology

Polypharmacy is common and especially challenging in the context of borderline personality disorder in light of impulsivity and self-harm associated with the disorder, risk of adverse drug-drug interactions, and financial burden. Reduction in polypharmacy could be conceptualized as a high priority in the treatment of borderline personality disorder. This case aims to demonstrate that potential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research